Humacyte, Inc. (NASDAQ:HUMA) Receives $8.14 Average Price Target from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $8.1429.

HUMA has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Benchmark decreased their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. UBS Group restated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Monday, January 5th.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.03 on Friday. The firm’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.56. The firm has a market capitalization of $192.89 million, a P/E ratio of -4.48 and a beta of 1.93. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. Humacyte has a 52 week low of $0.91 and a 52 week high of $4.85.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.92 million. Analysts anticipate that Humacyte will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Lazari Capital Management Inc. bought a new stake in Humacyte in the second quarter worth about $27,000. Truist Financial Corp bought a new stake in shares of Humacyte in the 3rd quarter worth approximately $28,000. Prudential Financial Inc. bought a new stake in shares of Humacyte in the 2nd quarter worth approximately $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte during the second quarter valued at approximately $28,000. Finally, Equitable Holdings Inc. bought a new stake in Humacyte during the third quarter worth approximately $29,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.